Monogenic diabetes in overweight and obese youth diagnosed with type 2 diabetes: The TODAY clinical trial

Genetics in Medicine

Volumn 20, Issue 6, 2018, Pages 583-590

  Kleinberger, Jeffrey W ^a   Copeland, Kenneth C ^b   Gandica, Rachelle G ^c   Haymond, Morey W ^d   Levitsky, Lynne L ^e   Linder, Barbara ^f   Shuldiner, Alan R ^a,g   Tollefsen, Sherida ^h   White, Neil H ⁱ   Pollin, Toni I ^a  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF OKLAHOMA COLLEGE OF MEDICINE   (United States)

^c Department of Medicine   (United States)

^d BAYLOR COLLEGE OF MEDICINE   (United States)

^e MASSACHUSETTS GENERAL HOSPITAL   (United States)

^f NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

^g AB)   (United States)

^h SAINT LOUIS UNIVERSITY   (United States)

ⁱ WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSE; HEMOGLOBIN A1C; INSULIN; METFORMIN; ROSIGLITAZONE; GERMINAL CENTER KINASES; HEPATOCYTE NUCLEAR FACTOR 1ALPHA; HEPATOCYTE NUCLEAR FACTOR 4; HNF1A PROTEIN, HUMAN; HNF4A PROTEIN, HUMAN; PROTEIN SERINE THREONINE KINASE;

ADOLESCENT; ADOLESCENT OBESITY; AMINO ACID SUBSTITUTION; ARTICLE; BODY MASS; CLINICAL TRIAL; DIABETIC OBESITY; DIET RESTRICTION; FEMALE; GCK GENE; GENE; GENETIC VARIABILITY; GENOTYPE; GLYCEMIC CONTROL; HNF1A GENE; HNF4A GENE; HUMAN; INDEL MUTATION; INS GENE; KLF11 GENE; LIFESTYLE MODIFICATION; MAJOR CLINICAL STUDY; MALE; MONOGENIC DISORDER; NON INSULIN DEPENDENT DIABETES MELLITUS; PATHOGENICITY; TIME TO TREATMENT; TREATMENT FAILURE; TREATMENT RESPONSE; CHILD; COHORT ANALYSIS; COMPLICATION; GENETICS; METABOLISM; OBESITY;

ADOLESCENT; BODY MASS INDEX; CHILD; COHORT STUDIES; DIABETES MELLITUS, TYPE 2; FEMALE; HEPATOCYTE NUCLEAR FACTOR 1-ALPHA; HEPATOCYTE NUCLEAR FACTOR 4; HUMANS; MALE; OBESITY; OVERWEIGHT; PROTEIN-SERINE-THREONINE KINASES;

EID: 85048274391     PISSN: 10983600     EISSN: 15300366     Source Type: Journal    
DOI: 10.1038/gim.2017.150     Document Type: Article

References (40)

1. Tattersall RB, Fajans SS. A difference between the inheritance of classical juvenile-onset and maturity-onset type diabetes of young people. Diabetes. 1975;24:44-53.
2. Murphy R, Ellard S, Hattersley AT. Clinical implications of a molecular genetic classification of monogenic beta-cell diabetes. Nat Clin Pract Endocrinol Metab. 2008;4:200-213.
3. Shepherd M, Shields B, Hammersley S, et al. Systematic population screening, using biomarkers and genetic testing, identifies 2.5% of the U.K. pediatric diabetes population with monogenic diabetes. Diabetes Care. 2016;39:1879-1888.
4. Weinreich SS, Bosma A, Henneman L, et al. A decade of molecular genetic testing for MODY: A retrospective study of utilization in the Netherlands. Eur J Hum Genet. 2015;23:29-33.
5. Delvecchio M, Ludovico O, Menzaghi C, et al. Low prevalence of HNF1A mutations after molecular screening of multiple MODY genes in 58 Italian families recruited in the pediatric or adult diabetes clinic from a single Italian hospital. Diabetes Care. 2014;37:e258-60.
6. Naylor RN, John PM, Winn AN, et al. Cost-effectiveness of MODY genetic testing: Translating genomic advances into practical health applications. Diabetes Care. 2014;37:202-209.
7. Shepherd M, Shields B, Ellard S, Rubio-Cabezas O, Hattersley AT. A genetic diagnosis of HNF1A diabetes alters treatment and improves glycaemic control in the majority of insulin-treated patients. Diabet Med. 2009;26:437-441.
8. Pearson ER, Pruhova S, Tack CJ, et al. Molecular genetics and phenotypic characteristics of MODY caused by hepatocyte nuclear factor 4alpha mutations in a large European collection. Diabetologia. 2005;48: 878-885.
9. Steele AM, Shields BM, Wensley KJ, Colclough K, Ellard S, Hattersley AT. Prevalence of vascular complications among patients with glucokinase mutations and prolonged, mild hyperglycemia. JAMA. 2014;311: 279-286.
10. American Diabetes Association. 2. Classification and diagnosis of diabetes. Diabetes Care. 2017;40(suppl 1):S11-S24.
11. Pihoker C, Gilliam LK, Ellard S, et al. Prevalence, characteristics and clinical diagnosis of maturity onset diabetes of the young due to mutations in HNF1A, HNF4A, and glucokinase: Results from the SEARCH for diabetes in youth. J Clin Endocrinol Metab. 2013;98:4055-4062.
12. TODAY Study Group, Zeitler P, Epstein L, et al. Treatment options for type 2 diabetes in adolescents and youth: A study of the comparative efficacy of metformin alone or in combination with rosiglitazone or lifestyle intervention in adolescents with type 2 diabetes. Pediatr Diabetes. 2007;8:74-87.
13. TODAY Study Group, Zeitler P, Hirst K, et al. A clinical trial to maintain glycemic control in youth with type 2 diabetes. N Engl J Med. 2012;366: 2247-2256.
14. Richards S, Aziz N, Bale S, et al. Standards and guidelines for the interpretation of sequence variants: A joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med. 2015;17:405-423.
15. Rothman KJ. No adjustments are needed for multiple comparisons. Epidemiology. 1990;1:43-46.
16. Writing Group for the SEARCH for Diabetes in Youth Study Group, Dabelea D, Bell RA, et al. Incidence of diabetes in youth in the United States. JAMA. 2007;297:2716-2724.
17. McDonald TJ, Colclough K, Brown R, et al. Islet autoantibodies can discriminate maturity-onset diabetes of the young (MODY) from type 1 diabetes. Diabet Med. 2011;28:1028-1033.
18. Wheeler BJ, Patterson N, Love DR, et al. Frequency and genetic spectrum of maturity-onset diabetes of the young (MODY) in southern New Zealand. J Diabetes Metab Disord. 2013;12:46-6581-12-46.
19. Chambers C, Fouts A, Dong F, et al. Characteristics of maturity onset diabetes of the young in a large diabetes center. Pediatr Diabetes. 2015;17:360-7.
20. Shields BM, Hicks S, Shepherd MH, Colclough K, Hattersley AT, Ellard S. Maturity-onset diabetes of the young (MODY): How many cases are we missing?. Diabetologia. 2010;53:2504-2508.
21. Pearson ER, Boj SF, Steele AM, et al. Macrosomia and hyperinsulinaemic hypoglycaemia in patients with heterozygous mutations in the HNF4A gene. PLoS Med. 2007;4:e118.
22. Wang Y, Gao E, Wu J, et al. Fetal macrosomia and adolescence obesity: Results from a longitudinal cohort study. Int J Obes (Lond). 2009;33: 923-928.
23. Stride A, Ellard S, Clark P, et al. Beta-cell dysfunction, insulin sensitivity, and glycosuria precede diabetes in hepatocyte nuclear factor-1alpha mutation carriers. Diabetes Care. 2005;28:1751-1756.
24. Fendler W, Rizzo M, Borowiec M, et al. Less but better: Cardioprotective lipid profile of patients with GCK-MODY despite lower HDL cholesterol level. Acta Diabetol. 2014;51:625-632.
25. McDonald TJ, McEneny J, Pearson ER, et al. Lipoprotein composition in HNF1A-MODY: Differentiating between HNF1A-MODY and type 2 diabetes. Clin Chim Acta. 2012;413:927-932.
26. Forlani G, Zucchini S, Di Rocco A, et al. Double heterozygous mutations involving both HNF1A/MODY3 and HNF4A/MODY1 genes: A case report. Diabetes Care. 2010;33:2336-2338.
27. Monney CT, Kaltenrieder V, Cousin P, Bonny C, Schorderet DF. Large family with maturity-onset diabetes of the young and a novel V121I mutation in HNF4A. Hum Mutat. 2002;20:230-231.
28. Gloyn AL, Noordam K, Willemsen MA, et al. Insights into the biochemical and genetic basis of glucokinase activation from naturally occurring hypoglycemia mutations. Diabetes. 2003;52:2433-2440.
29. Ellard S, Beards F, Allen LI, et al. A high prevalence of glucokinase mutations in gestational diabetic subjects selected by clinical criteria. Diabetologia. 2000;43:250-253.
30. Bertini C, Maioli M, Fresu P, Tonolo G, Pirastu M, Maioli M. A new missense mutation in the glucokinase gene in an Italian MODY family. Diabetologia. 1996;39:1413-1414.
31. Osbak KK, Colclough K, Saint-Martin C, et al. Update on mutations in glucokinase (GCK), which cause maturity-onset diabetes of the young, permanent neonatal diabetes, and hyperinsulinemic hypoglycemia. Hum Mutat. 2009;30:1512-1526.
32. Galan M, Vincent O, Roncero I, et al. Effects of novel maturityonset diabetes of the young (MODY)-associated mutations on glucokinase activity and protein stability. Biochem J. 2006;393(pt 1): 389-396.
33. Hattersley AT, Beards F, Ballantyne E, Appleton M, Harvey R, Ellard S. Mutations in the glucokinase gene of the fetus result in reduced birth weight. Nat Genet. 1998;19:268-270.
34. Bjorkhaug L, Ye H, Horikawa Y, Sovik O, Molven A, Njolstad PR. MODY associated with two novel hepatocyte nuclear factor-1alpha loss-offunction mutations (P112L and Q466X). Biochem Biophys Res Commun. 2000;279:792-798.
35. Frayling TM, Bulamn MP, Ellard S, et al. Mutations in the hepatocyte nuclear factor-1alpha gene are a common cause of maturity-onset diabetes of the young in the U.K. Diabetes. 1997;46:720-725.
36. Balamurugan K, Bjorkhaug L, Mahajan S, et al. Structure-function studies of HNF1A (MODY3) gene mutations in South Indian patients with monogenic diabetes. Clin Genet. 2016;90:486-495.
37. Ekholm E, Nilsson R, Groop L, Pramfalk C. Alterations in bile acid synthesis in carriers of hepatocyte nuclear factor 1alpha mutations. J Intern Med. 2013;274:263-272.
38. Neve B, Fernandez-Zapico ME, Ashkenazi-Katalan V, et al. Role of transcription factor KLF11 and its diabetes-associated gene variants in pancreatic beta cell function. Proc Natl Acad Sci U S A. 2005;102: 4807-4812.
39. Boesgaard TW, Pruhova S, Andersson EA, et al. Further evidence that mutations in INS can be a rare cause of maturity-onset diabetes of the young (MODY). BMC Med Genet. 2010;11:42-2350-11-42.
40. Molven A, Ringdal M, Nordbo AM, et al. Mutations in the insulin gene can cause MODY and autoantibody-negative type 1 diabetes. Diabetes. 2008;57:1131-1135.